GlassScriptPhysician profile
Joseph J Phillips
NPI 1013130186
$3,223.21
in general payments reported to CMS, 2019-2025
25 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $231 · 2021: $300 · 2022: $242 · 2023: $636 · 2024: $771 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.83 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $737.08 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $517.14 | 2023-2025 | Orgovyx, Gemtesa |
| Axonics, INC. | $298.55 | 2022-2024 | Axonics |
| Boston Scientific Corporation | $280.21 | 2019-2025 | Axonics, Lumenis Pulse 120h |
| Pfizer INC. | $237.42 | 2019-2025 | |
| Janssen Biotech, INC. | $204.32 | 2019-2024 | Erleada, Akeega, Balversa |
| Olympus America INC. | $175.21 | 2022-2024 | Itind System, Soltive |
| Neotract INC. | $159.01 | 2019 | |
| Procept Biorobotics Corporation | $111.72 | 2022-2024 | Aquabeam System |
| Coloplast Corp | $62.98 | 2020-2024 | |
| Antares Pharma, INC. | $54.67 | 2024-2025 | Xyosted |
| Endo Pharmaceuticals INC. | $51.05 | 2019-2023 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $45.90 | 2023-2024 | Pylarify |
| Amgen INC. | $44.25 | 2019-2021 | |
| Endo USA, INC. | $42.69 | 2024-2025 | Xiaflex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photocure INC | $35.71 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $31.03 | 2024 | Urgent PC Neuromodulation System |
| Tolmar, INC. | $23.33 | 2024 | |
| Allergan, INC. | $23.16 | 2019-2021 | |
| Glaxosmithkline, LLC. | $16.81 | 2025 | Bexsero |
| C. R. Bard, INC. & Subsidiaries | $15.40 | 2019 | |
| Ambu INC. | $15.33 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $14.14 | 2019 | |
| Abbvie INC. | $13.09 | 2024 | |
| Myovant Sciences INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.